Virgin Galactic Stock Is Only for Astronauts and Speculators – InvestorPlace

Virgin Galactic (NYSE:SPCE) is one of many companies in the market today where the numbers dont matter. SPCE stock is climbing despite the unknowns Virgin Galactic faces.

Source: Tun Pichitanon / Shutterstock.com

The company hopes to do intercontinental flights that briefly enter low Earth orbit. It hopes to do them cheaply by launching off larger planes before engaging on-board engines. It hopes to be offering commercial flights in a few years. Virgin Galactic even hopes to get you from the United States to Sydney in a few hours.

Meanwhile, the company struggles to perfect its system, prove its safety and keep generating the hype needed to stay in business.

Its a mark of just where the market is that, so far in 2020, that has gone quite well. The shares are up almost 30% year to date.

Until Elon Musks SpaceX or Jeff Bezos Blue Origin seek capital from the public markets, Virgin Galactic is the only crazy billionaire space stock.

The crazy billionaire in this case is Richard Branson. He has had to sell out what was a 46% holding in big tranches to support Virgin Atlantic, the airline he co-owns with Delta Air Lines (NYSE:DAL). Those sales went well. Since they also cleared out warrants Branson held, they were seen to be bullish.

Virgin Galactics efforts cost about $200 million per year. At the end of March, it still had $431 million of cash. The Federal Aviation Administration issued rules about private human space flight in March. But formal safety regulations wont arrive until 2023.

Until it can take passengers, Virgin Galactic stock is tied to the markets moods and the hype over commercial space travel.

When the market was in a good mood in February, before the novel coronavirus, SPCE stock traded as high as $40 per share. People went on TV to explain it, but there was nothing they could say. There was no news.

A second stage of speculation was a UBS report in March saying that using space as Virgin Galactic proposes could be a $20-billion business in 2030. The report said space tourism could be a $3-billion opportunity. If Virgin Galactic can get 100 passengers onto a flight, cutting travel times 80%, and charging $2,500 per ticket, the estimate could be conservative, UBS wrote.

The shares got a third boost in early June, after SpaceX sent two astronauts to the International Space Station. Shares rose 6% but, again, this was not news relevant to Virgin Galactic.

When forced to say yea or nay on SPCE stock, most analysts start dancing.

Making money with it isnt rocket science, InvestorPlaces David Moadel wrote recently. He recommended a low-key, patient approach. Ian Cooper looked at the same set of facts and suggested avoiding the stock. Virgin Galactic has been taking deposits on flights, worth $100 million in future revenue, but cant yet fulfill those contracts.

TV analyst Jim Cramer considers most of the action a game. There were spikes of short interest in February and in May. As much as 30% of the float is sometimes being borrowed on the hope of lower prices. Take away that pressure and the stock settles back to Earth.

There are stocks you invest in for income, stocks you invest in for capital appreciation and stocks you trade.

Virgin Galactic is a stock you trade.

Its system works in theory. The company has done some test flights. But until there are real flights, with paying passengers, its all a guess.

The stock will rise or fall with news, with the markets temperature with its own short interest. But, as Gertrude Stein said of Oakland, theres no there there. Until there is, risk-averse investors should stay on the sidelines, and leave SPCE stock to the speculators.

Dana Blankenhorn has been a financial and technology journalist since 1978. He is the author of the environmental thriller Bridget OFlynn and the Bear, available at the Amazon Kindle store. Follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this story.

More:

Virgin Galactic Stock Is Only for Astronauts and Speculators - InvestorPlace

The amazon bond offering – Nairametrics

Elon Musk is one of the many individuals that has played a crucial role in tech innovation. Musk is known all over the world for a number of companies and a variety of products.

Specifically, he is known as an engineer, industrial designer, technology entrepreneur and philanthropist. Tesla as his brain child has led the revolution of electric cars which have the potential to replace the polluting combustion engine-driven vehicles.

Tesla vehicles represent mans drive towards clean transportation; being able to move around without contaminating the air he breathes. In 2019, the company manufactured over 300,000 vehicles and generated about US$24.578 dollars. Thats a lot of money.

READ ALSO: Elon Musk fires back at SEC on twitter

Musk is also the progenitor of The Boring Company, an American Infrastructural and tunnel construction company founded in 2016. We cant also forget Open AI, an Artificial Intelligence company dedicated to ensuring AI does not lead to human extinction. Elon with regards to Open AI, shares the idea that AI, if not controlled can broaden its ability to re-design and improve itself which can be inimical for man. Because of this, the company partners with other organisations and researchers in the field to ensure AI remains an extension of human intelligence and not necessarily a competitor.

A company that will be of interest to any is SpaceX officially known as the Space Explosion Technologies Corp., an American aerospace manufacturing and space transportation company. SpaceX is not just a representation of Elons desire for space travel, but the deeper vision of colonizing Mars.

In 2017, SpaceX unveiled the Interplanetary Transport System, a privately funded system.

In 2020, SpaceX in collaboration with NASA launched two astronauts into space, the first launch since the U.S. government retired its space program after a national tragedy. It was also the first collaboration between NASA and a private organisation. This, however, does not seem to be the last launch for Elons company as the next launch is scheduled for June 12.

READ ALSO: Disruptive Opportunities: Can developing AI and robotics stabilise the Naira?

SpaceX will among other things, be sending another 60 of its starling satellites into orbit. Elon Musks works do not in any way undermine the products, innovations, researches and actions of others in the tech field. But they unsurprisingly put him at the forefront of it all.

How this affects the tech space and the rest of the world?Elons companies and their products are causing ripple effects in their respective industries. They are giving the old way of doing things a run for its money. His inventions and innovations ordinarily represent the tools of the new era of tech.

At the same time, he is becoming a threat to competitors in the tech industry. Kanyes West words, how can one man have all that power?! resonates in the minds of competitors and businessmen who want a slice of Elons cake.

Be this as it may, without worthy competitors, Elon will be left to dominate and control the trends in Artificial Intelligence, Space travel among others. This is not strange in any way. Once upon a time, we had Steve Jobs at the forefront of innovation in tech.

For consumers, Elons dominance in the tech field might be a little troublesome. Having innovative tech is good for us, but having them from the same person does not cut it. If that is to happen, the tech market will be dominated by Elon Musk and his many tech companies which could in more ways than one, limit the variety of products in our lives.

READ ALSO: Tech group suspends Crowdfunded relief to Nigerians

Moreover, tech could become monotonous being that the concepts emanated from the same mind. Governmental policies could also be affected by Elons dominance of the tech industry.

SpaceX launches, as much as they have a record of firsts, it wont be wrong to say that either subtly or not, the company and Elon has impacted governments policies; specifically, as regards space travel.

On the whole, these dont mean Elon Musk is an overbearing capitalist, but we need the tech industry to step up to match his innovations specifically in these fields: artificial intelligence, space travel, automobile and car manufacturing.

Read more:

The amazon bond offering - Nairametrics

Trending: Neurotechnology Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 – Cole of…

LOS ANGELES, United States: QY Research has recently published a report, titled Global Neurotechnology Market Size, Status and Forecast 2020-2026.The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Neurotechnology market. It informs readers about key trends and opportunities in the global Neurotechnology market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Neurotechnology market.

Key companies operating in the global Neurotechnology market include General Electric, Siemens Healthcare, Koninklijke Philips, Canon Medical Systems, Shimadzu, Hitachi Medical, Elekta, Tristan Technologies, Allengers Medical, Natus Medical, Magstim Neurotechnology

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1531676/global-neurotechnology-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Neurotechnology market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Neurotechnology Market Segment By Type:

, Imaging Modalities, Neurostimulation, Cranial Surface Measurement, Neurological Implants, Others

Global Neurotechnology Market Segment By Application:

, Hospitals, Clinics, Diagnostic Centers, Ambulatory Surgical Centers

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Neurotechnology market.

Key companies operating in the global Neurotechnology market include General Electric, Siemens Healthcare, Koninklijke Philips, Canon Medical Systems, Shimadzu, Hitachi Medical, Elekta, Tristan Technologies, Allengers Medical, Natus Medical, Magstim Neurotechnology

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1531676/global-neurotechnology-market

TOC

1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Neurotechnology Revenue1.4 Market by Type1.4.1 Global Neurotechnology Market Size Growth Rate by Type: 2020 VS 20261.4.2 Imaging Modalities1.4.3 Neurostimulation1.4.4 Cranial Surface Measurement1.4.5 Neurological Implants1.4.6 Others1.5 Market by Application1.5.1 Global Neurotechnology Market Share by Application: 2020 VS 20261.5.2 Hospitals1.5.3 Clinics1.5.4 Diagnostic Centers1.5.5 Ambulatory Surgical Centers1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends2.1 Global Neurotechnology Market Perspective (2015-2026)2.2 Global Neurotechnology Growth Trends by Regions2.2.1 Neurotechnology Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Neurotechnology Historic Market Share by Regions (2015-2020)2.2.3 Neurotechnology Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Neurotechnology Market Growth Strategy2.3.6 Primary Interviews with Key Neurotechnology Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Neurotechnology Players by Market Size3.1.1 Global Top Neurotechnology Players by Revenue (2015-2020)3.1.2 Global Neurotechnology Revenue Market Share by Players (2015-2020)3.1.3 Global Neurotechnology Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Neurotechnology Market Concentration Ratio3.2.1 Global Neurotechnology Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Neurotechnology Revenue in 20193.3 Neurotechnology Key Players Head office and Area Served3.4 Key Players Neurotechnology Product Solution and Service3.5 Date of Enter into Neurotechnology Market3.6 Mergers & Acquisitions, Expansion Plans 4 Market Size by Type (2015-2026)4.1 Global Neurotechnology Historic Market Size by Type (2015-2020)4.2 Global Neurotechnology Forecasted Market Size by Type (2021-2026) 5 Market Size by Application (2015-2026)5.1 Global Neurotechnology Market Size by Application (2015-2020)5.2 Global Neurotechnology Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Neurotechnology Market Size (2015-2020)6.2 Neurotechnology Key Players in North America (2019-2020)6.3 North America Neurotechnology Market Size by Type (2015-2020)6.4 North America Neurotechnology Market Size by Application (2015-2020) 7 Europe7.1 Europe Neurotechnology Market Size (2015-2020)7.2 Neurotechnology Key Players in Europe (2019-2020)7.3 Europe Neurotechnology Market Size by Type (2015-2020)7.4 Europe Neurotechnology Market Size by Application (2015-2020) 8 China8.1 China Neurotechnology Market Size (2015-2020)8.2 Neurotechnology Key Players in China (2019-2020)8.3 China Neurotechnology Market Size by Type (2015-2020)8.4 China Neurotechnology Market Size by Application (2015-2020) 9 Japan9.1 Japan Neurotechnology Market Size (2015-2020)9.2 Neurotechnology Key Players in Japan (2019-2020)9.3 Japan Neurotechnology Market Size by Type (2015-2020)9.4 Japan Neurotechnology Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Neurotechnology Market Size (2015-2020)10.2 Neurotechnology Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Neurotechnology Market Size by Type (2015-2020)10.4 Southeast Asia Neurotechnology Market Size by Application (2015-2020) 11 India11.1 India Neurotechnology Market Size (2015-2020)11.2 Neurotechnology Key Players in India (2019-2020)11.3 India Neurotechnology Market Size by Type (2015-2020)11.4 India Neurotechnology Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Neurotechnology Market Size (2015-2020)12.2 Neurotechnology Key Players in Central & South America (2019-2020)12.3 Central & South America Neurotechnology Market Size by Type (2015-2020)12.4 Central & South America Neurotechnology Market Size by Application (2015-2020) 13 Key Players Profiles13.1 General Electric13.1.1 General Electric Company Details13.1.2 General Electric Business Overview13.1.3 General Electric Neurotechnology Introduction13.1.4 General Electric Revenue in Neurotechnology Business (2015-2020))13.1.5 General Electric Recent Development13.2 Siemens Healthcare13.2.1 Siemens Healthcare Company Details13.2.2 Siemens Healthcare Business Overview13.2.3 Siemens Healthcare Neurotechnology Introduction13.2.4 Siemens Healthcare Revenue in Neurotechnology Business (2015-2020)13.2.5 Siemens Healthcare Recent Development13.3 Koninklijke Philips13.3.1 Koninklijke Philips Company Details13.3.2 Koninklijke Philips Business Overview13.3.3 Koninklijke Philips Neurotechnology Introduction13.3.4 Koninklijke Philips Revenue in Neurotechnology Business (2015-2020)13.3.5 Koninklijke Philips Recent Development13.4 Canon Medical Systems13.4.1 Canon Medical Systems Company Details13.4.2 Canon Medical Systems Business Overview13.4.3 Canon Medical Systems Neurotechnology Introduction13.4.4 Canon Medical Systems Revenue in Neurotechnology Business (2015-2020)13.4.5 Canon Medical Systems Recent Development13.5 Shimadzu13.5.1 Shimadzu Company Details13.5.2 Shimadzu Business Overview13.5.3 Shimadzu Neurotechnology Introduction13.5.4 Shimadzu Revenue in Neurotechnology Business (2015-2020)13.5.5 Shimadzu Recent Development13.6 Hitachi Medical13.6.1 Hitachi Medical Company Details13.6.2 Hitachi Medical Business Overview13.6.3 Hitachi Medical Neurotechnology Introduction13.6.4 Hitachi Medical Revenue in Neurotechnology Business (2015-2020)13.6.5 Hitachi Medical Recent Development13.7 Elekta13.7.1 Elekta Company Details13.7.2 Elekta Business Overview13.7.3 Elekta Neurotechnology Introduction13.7.4 Elekta Revenue in Neurotechnology Business (2015-2020)13.7.5 Elekta Recent Development13.8 Tristan Technologies13.8.1 Tristan Technologies Company Details13.8.2 Tristan Technologies Business Overview13.8.3 Tristan Technologies Neurotechnology Introduction13.8.4 Tristan Technologies Revenue in Neurotechnology Business (2015-2020)13.8.5 Tristan Technologies Recent Development13.9 Allengers Medical13.9.1 Allengers Medical Company Details13.9.2 Allengers Medical Business Overview13.9.3 Allengers Medical Neurotechnology Introduction13.9.4 Allengers Medical Revenue in Neurotechnology Business (2015-2020)13.9.5 Allengers Medical Recent Development13.10 Natus Medical13.10.1 Natus Medical Company Details13.10.2 Natus Medical Business Overview13.10.3 Natus Medical Neurotechnology Introduction13.10.4 Natus Medical Revenue in Neurotechnology Business (2015-2020)13.10.5 Natus Medical Recent Development13.11 Magstim10.11.1 Magstim Company Details10.11.2 Magstim Business Overview10.11.3 Magstim Neurotechnology Introduction10.11.4 Magstim Revenue in Neurotechnology Business (2015-2020)10.11.5 Magstim Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

Follow this link:

Trending: Neurotechnology Market 2020- Analysis And In-Depth Research On Market Size, Trends, Emerging Growth Factors And Forecast To 2026 - Cole of...

Growth of Facial Recognition Technology Market has been derived from the growing CAGR 2020-2028 – WorldsTrend

Facial Recognition Technology Market is analyzed with industry experts in mind to maximize return on investment by providing clear information needed for informed business decisions. This research will help both established and new entrants to identify and analyze market needs, market size and competition. It explains the supply and demand situation, the competitive scenario, and the challenges for market growth, market opportunities and the threats faced by key players.

Sample Copy of This Report: https://www.quincemarketinsights.com/request-sample-39892?utm_source=WT/komal

A 360 degree outline of the competitive scenario of the Global Facial Recognition Technology Market is presented by Quince Market Insights. It has a massive data allied to the recent product and technological developments in the markets.

It has a wide-ranging analysis of the impact of these advancements on the markets future growth, wide-ranging analysis of these extensions on the markets future growth. The research report studies the market in a detailed manner by explaining the key facets of the market that are foreseeable to have a countable stimulus on its developing extrapolations over the forecast period.

Companies Covered:NEC Corporation, Aware, Gemalto, Ayonix Face Technologies, Cognitec Systems GmbH, NVISO SA, Daon, StereoVision Imaging, Techno Brain, Neurotechnology, Innovatrics, id3 Technologies, IDEMIA, Animetrics, MEGVII, Idemia, Gemalto NV, Ayonix Corporation, Herta Security, Keylemon SA., Cross Match Technologies, ZK Software, Safran Group (Morpho S.A.), FaceFirst LLC, 3M Cogent Inc., and Animetrics Inc.

Reasons for buying this report:

By Technology (2D Facial Recognition, 3D Facial Recognition, and Facial Analytics), By Component (Software, Hardware, and Services), By Application (Law Enforcement, Border Security, Emotion Recognition, Attendance Tracking & Monitoring, Access Control, Homeland Security, Criminal Investigation, Identity Management, Physical Security, Intelligent Signage, Photo Indexing & Sorting, Business Intelligence, and Others), By End User (Government, Medical & Healthcare, Commercial, Military & Defense, and Others)

Get ToC for the overview of the premium report @ https://www.quincemarketinsights.com/request-toc-39892?utm_source=WT/komal

A detailed outline of the Global Facial Recognition Technology Market includes a comprehensive analysis of different verticals of businesses. North America, Europe, Asia Pacific, Middle East & Africa, and South America have been considered for the studies on the basis of several terminologies.

This is anticipated to drive the Global Facial Recognition Technology Market over the forecast period. This research report covers the market landscape and its progress prospects in the near future. After studying key companies, the report focuses on the new entrants contributing to the growth of the market. Most companies in the Global Facial Recognition Technology Market are currently adopting new technological trends in the market.

Finally, the researchers throw light on different ways to discover the strengths, weaknesses, opportunities, and threats affecting the growth of the Global Facial Recognition Technology Market. The feasibility of the new report is also measured in this research report.

Make an Enquiry for purchasing this Report @ https://www.quincemarketinsights.com/enquiry-before-buying-39892?utm_source=WT/komal

Table of Contents:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Ajay D. (Knowledge Partner)

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 121 364 6144

Email: sales@quincemarketinsights.com

Web: https://www.quincemarketinsights.com

Go here to see the original:

Growth of Facial Recognition Technology Market has been derived from the growing CAGR 2020-2028 - WorldsTrend

Meet 10 Companies Working On Reading Your Thoughts (And Even Those Of Your Pets) – Forbes

Brain-machine interfaces (BMI) and brain-computer interfaces (BCI) are devices that enable direct ... [+] communication between a brain and an external device.

Philosopher John Locke said, I have always thought the actions of men the best interpreters of their thoughts. Locke lived during the Age of Enlightenment. He probably wasnt thinking about human machine actions during his philosophical ponderings. But what does it mean when machine actions are the result of human thoughts? No longer part of science fiction, many would argue that brain-machine and brain-computer interfaces are the next way we will communicate with machines and even with one another.

Brain-machine interfaces (BMI) and brain-computer interfaces (BCI) are devices that enable direct communication between a brain and an external device. BCIs let someone type onto a screen without a keyboard. Brain-machine interfaces make it possible for amputees to move robotic limbs. BCIs can be as intricate as placing devices directly on the brain or via devices that communicate directly to machines without invasive surgery.

This type of technology opens a whole world of business applications. From dangerous jobs that already utilize robots to manufacturing, and even the consumer space. Brain-machine interfaces create a new way for humans to interact with technology, whether it be their smartphones, smart speakers, voice assistants, cars, and even each other. Startups and established companies alike realize the promise of brain-machine interfaces. They are racing to link humans to tech and machines, allowing humans to control digital technology using only their minds, which in turn opens up a whole new world of opportunities for businesses and brands to reach the customer of the future.

Here are 10 companies that are working on connecting our brains or actions to our machines and creating the future of input.

Testing out Neurable at FutureX Live in Atlanta in April 2019.

Neurables mission is very exciting. Ramses Alcaide, founder of Neurable, got the idea for helping people with technology when he was a kid after his uncle lost his legs in a trucking accident. Alcaide said, the idea of developing technology for people who are differently abled has been my big, never-ending quest. Neurable launched onto the brain-computer interface scene in 2017 at SIGGRAPH with a proof of concept BCI game called The Awakening. Users put on a VR headset to escape from a room with only their minds. In December 2019, Neurable raised a $6 million Series A round to develop an everyday consumer based brain-computer interface in the form of headphones.

Alcaide sees neurotechnology built into a pair of headphones as the first step towards a BCI for consumers. Think about stopping, starting, or skipping songs with your mind without ever touching your phone. Interacting with smart devices with just our thoughts through a headphone-like device is impressive enough on its own. For Neurable, its the data behind the interactions that show the real value of BCIs.

Cognitive analytics are, measures of different mental states, especially those aligned with performance. BCI enabled headphones could help a person, enter their desired emotion and then have a customized playlist generated to provoke that response. Not to mention open a whole new world of metrics for marketers, training, health professionals, and a variety of other industries. Alcaide believes computing is going to become more spatial. He said, As it continues to go down that path, we need forms of interaction that enable us to more seamlessly interact with our technology.

MindX believes the next frontier in computing is a direct link from the brain to the digital world. Theyre creating this link by combining neurotechnology, augmented reality and artificial intelligence to create a "look-and-think interface for next-generation spatial computing applications. Part of spatial computing, is being able to interact with computers beyond a two-dimensional screen.

MindX uses smart glasses to create a link between human brains and technology. Julia Brown, MindXs CEO, said smart glasses will let wearers access information with a single thought. Glasses connect to the mind from eye movements. Brain waves signal back what the wearer is thinking and where they are looking. BCI enabled smart glasses opens a world of opportunities for visual search. Think about your lost car keys and the smart glasses can locate them. Wonder what someone is wearing and get the brand and link to places to buy from the glasses - all with a thought.

While some brain-computer interface companies focus on understanding the brain and cognitive metrics, others focus on real-time device control. NextMind, headquartered in Paris, France, uses a non-invasive BMI that translates brain signals instantly from the user's visual cortex into digital commands for any device in real-time. NextMind debuted their device at CES 2020. Visitors to the booth demoed changing channels on a TV with just their thoughts.

Testing the NextMind device at CES 2020 and using thoughts to turn on lights and dim them.

Users wear NextMind on the back of their heads. It creates a symbiotic connection with the digital world by combining neural networks and neural signals. The Next Mind SDK is open to developers. Theyre at a price point that the industry believes consumers are ready for the next phase in computer interaction.

Unboxing Neurosity's Notion developer's kit in January 2020.

Neurositys goal is to help developers get focused faster and stay focused longer. Notion (Neurositys thought-powered computer) has eight sensors as part of an EEG headset. In their demo, a woman scrolls through a recipe on her tablet while cooking. In another, a man changes the lighting in the room with his mind. The Notion brain sensor can be pre-ordered. The device touts its secure design saying, it never stores your brainwaves. Something to look out for in a BCI.

Neurosity launched dev kits in 2019. The Neurosity developer community is one of the signs that brain-computer interfaces have arrived. Developers can write apps for Notions brain sensor, which is developed to do two things: to detect human intent and to quantify the self. Think of it like wearing a fitness tracker for the brain. In April 2020, Neurosity temporarily cut the price of Notion pre-orders to $799 for developers. Neurosity pledges their support to developers interested in helping quantify the human mind even further by making their team available to brainstorm, code, and deploy neuro apps.

Kernel is a neurotechnology company based in Los Angeles, California. Their aim is to create a brain interface that develops real-world applications of high-resolution brain activity. Kernals founder and CEO, Bryan Johnson, believes in a world where people are empowered by technology, not limited by it. He sees neuroscience, specifically Kernals neuroscience as a service (NaaS) as a way to get there. Kernel was featured in I Am Human, a 2020 award-winning documentary about the the scientists and entrepreneurs on a quest to unlock the secrets of the brain.

Kernel created two different experiments with their technology. One is Speller which allows participants to type with only their gaze and a visual keyboard. The other is Sound ID that can decode song IDs based on the brain signals from the listener. These experiments show that with just a helmet, brain scientists can run the same type of experiments as those in labs with room size equipment. With the use of a helmet, brain scientists can study thousands of more people than they can currently. Johnson believes this can help people who have suffered strokes and are unable to speak or those dealing with mental disorders.

There are so many applications when it comes to brain-machine interfaces and neuroscience. Nectomes technology is developed to preserve human memory by studying how the brain physically creates memories. Nectome isnt just creating a BMI for the present. Theyre hoping to change how people preserve the languages, cultures, and wisdom of the past, and how health care engages with individuals memories and personal narratives.

President of Y Combinator, Sam Altman, is one of 25 people who have put down a $10,000 refundable deposit to join a waiting list at Nectome. The only catch is, Nectome needs a living brain to capture the memories. The procedure kills the patient. Nectome planned to test it with terminally ill volunteers in California, which permits doctor-assisted suicide for those patients. Sam said of the procedure, I assume my brain will be uploaded to the cloud. The startup has faced some setbacks but seems to still be in operation.

Eventually, Nectome believes their biological preservation techniques will be like an episode from Amazons Upload TV series. At the end of their life, patients can choose to upload themselves into a digital afterlife.

CRTL-Labs uses non-invasive neural interfaces to expand human bandwidth. CRTL-Labs recreates the 0s and 1s of neurons by listening to muscle twitches. They send the signals into machine learning to decode a persons intention. This network is fed back to the wearer to create a symbiotic relationship. Thomas Reardon, CEO of CRTL-Labs said, AI and Machine Learning can be dominated by us. CRTL-Labs does all of this with a wristband.

Facebooks leadership have talked about a new type of interface that includes work around direct brain interfaces that are going to, eventually, one day, let you communicate using only your mind. In September 2019, they bought CRTL-Labs and have said the following about the acquisition, The goal is to eventually make it so that you can think something and control something in virtual or augmented reality.

Neuralink is a company owned by none other than Elon Musk. The man who made electric cars cool (Tesla) and sends astronauts to space is his own spacecraft (SpaceX) also wants to connect humans to machines. Neuralink takes a slightly different approach to brain-machine interfaces by placing threads into the brain. Elon Musk wants his brain implants to stop humans being outpaced by artificial intelligence.

Neuralink threads are connected to a 4mm chip called the N1. The chips are placed close to important parts of the brain and are able to detect messages as they are relayed between neurons, recording each impulse and stimulating their own. The chip connects to a wireless device worn over the ear which is Bluetooth enabled. Currently, the chip is placed via traditional brain surgery but Musk envisions the chip will be inserted virtually painlessly in the future. Applications for the Neuralink are endless - from treating neurological disorders to replacing language, and eventually turning humans into cyborgs.

Paradromics developed brain-computer interface technology to help those disconnected from the world by mental illness, paralysis, or other types of brain disorders. Paradromics believes they can meet medical challenges with technical solutions. That is, a high-data rate brain-computer interface. Similar to the Neuralink, Paradromics places electrode arrays on the brain. They do this with a computer chip that plugs into a part of the brain called the cortex. With Paradromics technology, mental disorders and injuries no longer have to be debilitating. They can connect those affected back to the world.

Brain-computer interfaces arent just for people. Zoolingua, owned by Con Slobodchikoff, wants people to understand dogs. Their device will allow both dog and human to communicate in both directions. The translating dog collar from the movie UP is coming to real life. Zoolingua bases their technology on research. Observing (through video) dog vocalizations and behavior in specific contexts; classifying the complex forms of communication that occur; and working with computer programs to effectively and accurately decode and translate into US-English.

According to an Amazon report, advances in AI and machine learning will enable companies to make devices that can accurately translate a cats meows and a dogs barks into English. William Higham, co-author of the report, believes devices that can talk dog could be less than 10 years away.

All these companies are working on the future of input.

Separate from Zoolingua, another example of someone working on decoding Fidos thoughts is Dr. Gregory Berns from Emory University. He is a neuroscientist whos also interested in what dogs think. Dr. Berns developed a go/no-go test to scan dog brains in M.R.I machines. The results show dogs use corresponding parts of their brain to solve similar tasks as people do. This isnt something seen in non-primates before.

Neuroscience technology is a quickly developing field. Its one with endless applications for understanding the brain, unlocking human potential, and preserving todays minds for the future. Some of the companies listed above are working towards specific use cases. Some use direct-brain sensors while others use non-invasive devices.

What each brain-machine interface company has in common is that they see the world as a connected place. Its going to become even more so. The future of computing is beyond two-dimensional interactions. Its more than voice, facial recognition, artificial intelligence, and augmented reality.

Its all these things coming together under the power of the human brain.

Excerpt from:

Meet 10 Companies Working On Reading Your Thoughts (And Even Those Of Your Pets) - Forbes

Chitosan Coating of TiO2 Nanotube Arrays for Improved Metformin Releas | IJN – Dove Medical Press

Amir Hashemi,1 Masoumeh Ezati,2 Javad Mohammadnejad,3 Behzad Houshmand,4 Shahab Faghihi5

1Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran 14395-1561, Iran; 2Tissue Engineering and Biomaterials Research Center, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran 14965/161, Iran; 3Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran 14395-1561, Iran; 4Department of Periodontics, School of Dentistry, Shahid Beheshti University of Medical Sciences, Tehran 19857-17443, Iran; 5Tissue Engineering and Biomaterials Research Center, National Institute of Genetic Engineering and Biotechnology (NIGEB), Tehran 14965/161, Iran

Correspondence: Javad Mohammadnejad; Shahab Faghihi Tel +9821 8609-3078Tel/ Fax +98 21 44787386Fax +98(21)88497324Email mohamadnejad@ut.ac.ir; sfaghihi@nigeb.ac.ir

Background: Ineffective integration has been recognized as one of the major causes of early orthopedic failure of titanium-based implants. One strategy to address this problem is to develop modified titanium surfaces that promote osteoblast differentiation. This study explored titanium surfaces modified with TiO2 nanotubes (TiO2 NTs) capable of localized drug delivery into bone and enhanced osteoblast cell differentiation.Materials and Methods: Briefly, TiO2 NTs were subjected to anodic oxidation and loaded with Metformin, a widely used diabetes drug. To create surfaces with sustainable drug-eluting characteristics, TiO2 NTs were spin coated with a thin layer of chitosan. The surfaces were characterized via scanning electron microscopy, atomic force microscopy, and contact angle measurements. The surfaces were then exposed to mesenchymal bone marrow stem cells (MSCs) to evaluate cell adhesion, growth, differentiation, and morphology on the modified surfaces.Results: A noticeable increase in drug release time (3 days vs 20 days) and a decrease in burst release characteristics (85% to 7%) was observed in coated samples as compared to uncoated samples, respectively. Chitosan-coated TiO2 NTs exhibited a considerable enhancement in cell adhesion, proliferation, and genetic expression of type I collagen, and alkaline phosphatase activity as compared to uncoated TiO2 NTs.Conclusion: TiO2 NT surfaces with a chitosan coating are capable of delivering Metformin to a bone site over a sustained period of time with the potential to enhance MSCs cell attachment, proliferation, and differentiation.

Keywords: titania nanotubes, titanium, osteogenic differentiation, anodization, mesenchymal bone marrow stem cells, MSCs

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Excerpt from:

Chitosan Coating of TiO2 Nanotube Arrays for Improved Metformin Releas | IJN - Dove Medical Press

Ginkgo Bioworks CEO on scaling up Covid-19 testing: ‘If we try, we can win’ – CNBC

As businesses and schools seek to reopen, most public health experts agree that Covid-19 testing is needed more than ever.

The team behind Ginkgo Bioworks, a genetic engineering start-up, is going all in.

Using equipment from Illumina, a maker of DNA sequencing machines, the company which made CNBC's 2020 Disruptor 50 list is working on technology to run a half million tests per day, said Jason Kelly, Ginkgo's co-founder and CEO.The technology, if approved by federal regulators, will be saliva-based, which in theory would make it easier for consumers to get tested than using the nasal swabs most tests employ today.

"We didn't initially have enough tests, but now we've ramped up to about 400,000 per day," he said. "That's enough for our clinical diagnostics needs. ... However, we are now entering phase 2 of this thing."

Ginkgo, a darling of the burgeoning synthetic biology sector, got its start in 2009 when a group of MIT scientists got together to develop biotechnology tools for industries including agriculture, pharmaceuticals and cosmetics. In essence, it develops custom microorganisms that aim to replace technology with biology. Think of it as a way to program cells, a bit like you'd program computers.

"We program DNA and cells to make them do new things," said Kelly, who describes the company as the largest designers of "printing DNA" in the world.

The Boston-based company has raised close to $1 billion to date, as investors clamor to throw money into companies at the intersection of health care and technology. Kelly maintains that enthusiasm is warranted. The cost of sequencing DNA data is coming down faster than the cost of processing data on computers,outpacingMoore's law.

As Kelly puts it, "the chips aren't getting that much faster," but in biology things are "exponentially improving."

Right now Kelly believes Ginkgo can best apply its technology to help ramp up coronavirus testing in the U.S.

As the CEO explained, the initial crop of tests were primarily used to determine if people experiencing Covid-19 symptoms did, in fact, have the virus. But now, as people are going back to their lives, there will be an increasing need for regular testing of people who don't have symptoms.

For instance, Amazon plans to test its fulfillment center workers every two weeks, as well as monitor outbreaks in the community.

That means the country is going to need a lot more coronavirus tests.

Ginkgo started surveyingthe various techniques to scale up testing back in the spring, including antigen (a technology that looks for viral surface proteins), CRISPR-based (a genome editing technique) and next-generation sequencing approaches. Companies have only recently been granted emergency-use authorizations from the U.S. Food and Drug Administration for these types of tests. All of them, if ramped up, could theoretically augment the polymerase chain reaction tests that are currently the gold standard for Covid-19.

Ginkgo has decided to focus on next-generation sequencing with Illumina, which has already been granted an emergency-use approvalfor its Covid-19 test that is designed to sequence the full genome of the virus.

"Beyond diagnostic testing, Illumina and a number of our customers are exploring NGS-based workflows to enable high-volume screening to support a return to work and school," Illumina CEO Francis deSouza said in a statement.

In May Ginkgo announced it had raised another $70 million, including from Illumina, to fund its expansion in the diagnostics field. It is also using the money tobuild out its own testing facility in its highly automated Boston Seaport labs.

More from Disruptor 50:Moderna CEO sees success with Covid-19 vaccineThe technology that will dominate daily life on the other side of coronavirusCLEAR poised to lead in biometric screening for Covid

Kelly can't predict exactly when the company will be rolling out its tests, but it hopes to get FDA approval this summer. He said the company is already starting to work with businesses to help advise them as they determine how to safely get employees back to work. Many are concerned about a potential second shutdown if there's another outbreak in their area.

He believes that testing and contact tracing, where government officials track down and warn people who might have been exposed to Covid-19, are key to reopening the economy.

"I'm also sensing that a lot of people don't have a ton of hope," Kelly said. "Now we have to really try. If we try, we can win."

More:

Ginkgo Bioworks CEO on scaling up Covid-19 testing: 'If we try, we can win' - CNBC

CRISPR And CRISPR-Associated (Cas) Genes Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast…

Los Angeles, United State: Complete study of the global CRISPR And CRISPR-Associated (Cas) Genes market is carried out by the analysts in this report, taking into consideration key factors like drivers, challenges, recent trends, opportunities, advancements, and competitive landscape. This report offers a clear understanding of the present as well as future scenario of the global CRISPR And CRISPR-Associated (Cas) Genes industry. Research techniques like PESTLE and Porters Five Forces analysis have been deployed by the researchers. They have also provided accurate data on CRISPR And CRISPR-Associated (Cas) Genes production, capacity, price, cost, margin, and revenue to help the players gain a clear understanding into the overall existing and future market situation.

The research study includes great insights about critical market dynamics, including drivers, restraints, trends, and opportunities. It also includes various types of market analysis such as competitive analysis, manufacturing cost analysis, manufacturing process analysis, price analysis, and analysis of market influence factors. It is a complete study on the global CRISPR And CRISPR-Associated (Cas) Genes market that can be used as a set of effective guidelines for ensuring strong growth in the coming years. It caters to all types of interested parties, viz. stakeholders, market participants, investors, market researchers, and other individuals associated with the CRISPR And CRISPR-Associated (Cas) Genes business.

Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart)https://www.qyresearch.com/sample-form/form/958288/global-crispr-and-crispr-associated-cas-genes-market

It is important for every market participant to be familiar with the competitive scenario in the global CRISPR And CRISPR-Associated (Cas) Genes industry. In order to fulfil the requirements, the industry analysts have evaluated the strategic activities of the competitors to help the key players strengthen their foothold in the market and increase their competitiveness.

Key Players Mentioned in the Global CRISPR And CRISPR-Associated (Cas) Genes Market Research Report: , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation by Product: Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering

Global CRISPR And CRISPR-Associated (Cas) Genes Market Segmentation by Application: , Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes

The report has classified the global CRISPR And CRISPR-Associated (Cas) Genes industry into segments including product type and application. Every segment is evaluated based on growth rate and share. Besides, the analysts have studied the potential regions that may prove rewarding for the CRISPR And CRISPR-Associated (Cas) Genes manufcaturers in the coming years. The regional analysis includes reliable predictions on value and volume, thereby helping market players to gain deep insights into the overall CRISPR And CRISPR-Associated (Cas) Genes industry.

Additionally, the industry analysts have studied key regions including North America, Europe, Asia Pacific, Latin America, and Middle East and Africa, along with their respective countries. Here, they have given a clear-cut understanding of the present and future situations of the global CRISPR And CRISPR-Associated (Cas) Genes industry in key regions. This will help the key players to focus on the lucrative regional markets.

Key questions answered in the report:

Request for customization in Report:https://www.qyresearch.com/customize-request/form/958288/global-crispr-and-crispr-associated-cas-genes-market

Table of Content

Table of Contents Executive Summary 1 CRISPR And CRISPR-Associated (Cas) Genes Market Overview1.1 Product Overview and Scope of CRISPR And CRISPR-Associated (Cas) Genes1.2 CRISPR And CRISPR-Associated (Cas) Genes Segment by Type1.2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Production Growth Rate Comparison by Type (2014-2025)1.2.2 Genome Editing1.2.3 Genetic engineering1.2.4 gRNA Database/Gene Librar1.2.5 CRISPR Plasmid1.2.6 Human Stem Cells1.2.7 Genetically Modified Organisms/Crops1.2.8 Cell Line Engineering1.3 CRISPR And CRISPR-Associated (Cas) Genes Segment by Application1.3.1 CRISPR And CRISPR-Associated (Cas) Genes Consumption Comparison by Application (2014-2025)1.3.2 Biotechnology Companies1.3.3 Pharmaceutical Companies1.3.4 Academic Institutes1.3.5 Research and Development Institutes1.3 Global CRISPR And CRISPR-Associated (Cas) Genes Market by Region1.3.1 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size Region1.3.2 North America Status and Prospect (2014-2025)1.3.3 Europe Status and Prospect (2014-2025)1.3.4 China Status and Prospect (2014-2025)1.3.5 Japan Status and Prospect (2014-2025)1.3.6 Southeast Asia Status and Prospect (2014-2025)1.3.7 India Status and Prospect (2014-2025)1.4 Global CRISPR And CRISPR-Associated (Cas) Genes Market Size1.4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue (2014-2025)1.4.2 Global CRISPR And CRISPR-Associated (Cas) Genes Production (2014-2025) 2 Global CRISPR And CRISPR-Associated (Cas) Genes Market Competition by Manufacturers2.1 Global CRISPR And CRISPR-Associated (Cas) Genes Production Market Share by Manufacturers (2014-2019)2.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Share by Manufacturers (2014-2019)2.3 Global CRISPR And CRISPR-Associated (Cas) Genes Average Price by Manufacturers (2014-2019)2.4 Manufacturers CRISPR And CRISPR-Associated (Cas) Genes Production Sites, Area Served, Product Types2.5 CRISPR And CRISPR-Associated (Cas) Genes Market Competitive Situation and Trends2.5.1 CRISPR And CRISPR-Associated (Cas) Genes Market Concentration Rate2.5.2 CRISPR And CRISPR-Associated (Cas) Genes Market Share of Top 3 and Top 5 Manufacturers2.5.3 Mergers & Acquisitions, Expansion 3 Global CRISPR And CRISPR-Associated (Cas) Genes Production Market Share by Regions3.1 Global CRISPR And CRISPR-Associated (Cas) Genes Production Market Share by Regions3.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Regions (2014-2019)3.3 Global CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)3.4 North America CRISPR And CRISPR-Associated (Cas) Genes Production3.4.1 North America CRISPR And CRISPR-Associated (Cas) Genes Production Growth Rate (2014-2019)3.4.2 North America CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)3.5 Europe CRISPR And CRISPR-Associated (Cas) Genes Production3.5.1 Europe CRISPR And CRISPR-Associated (Cas) Genes Production Growth Rate (2014-2019)3.5.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)3.6 China CRISPR And CRISPR-Associated (Cas) Genes Production (2014-2019)3.6.1 China CRISPR And CRISPR-Associated (Cas) Genes Production Growth Rate (2014-2019)3.6.2 China CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)3.7 Japan CRISPR And CRISPR-Associated (Cas) Genes Production (2014-2019)3.7.1 Japan CRISPR And CRISPR-Associated (Cas) Genes Production Growth Rate (2014-2019)3.7.2 Japan CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019) 4 Global CRISPR And CRISPR-Associated (Cas) Genes Consumption by Regions4.1 Global CRISPR And CRISPR-Associated (Cas) Genes Consumption by Regions4.2 North America CRISPR And CRISPR-Associated (Cas) Genes Consumption (2014-2019)4.3 Europe CRISPR And CRISPR-Associated (Cas) Genes Consumption (2014-2019)4.4 China CRISPR And CRISPR-Associated (Cas) Genes Consumption (2014-2019)4.5 Japan CRISPR And CRISPR-Associated (Cas) Genes Consumption (2014-2019) 5 Global CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price Trend by Type5.1 Global CRISPR And CRISPR-Associated (Cas) Genes Production Market Share by Type (2014-2019)5.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue Market Share by Type (2014-2019)5.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price by Type (2014-2019)5.4 Global CRISPR And CRISPR-Associated (Cas) Genes Production Growth by Type (2014-2019) 6 Global CRISPR And CRISPR-Associated (Cas) Genes Market Analysis by Applications6.1 Global CRISPR And CRISPR-Associated (Cas) Genes Consumption Market Share by Application (2014-2019)6.2 Global CRISPR And CRISPR-Associated (Cas) Genes Consumption Growth Rate by Application (2014-2019) 7 Company Profiles and Key Figures in CRISPR And CRISPR-Associated (Cas) Genes Business7.1 Caribou Biosciences7.1.1 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.1.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.1.3 Caribou Biosciences CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.1.4 Main Business and Markets Served7.2 Addgene7.2.1 Addgene CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.2.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.2.3 Addgene CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.2.4 Main Business and Markets Served7.3 CRISPR THERAPEUTICS7.3.1 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.3.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.3.3 CRISPR THERAPEUTICS CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.3.4 Main Business and Markets Served7.4 Merck KGaA7.4.1 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.4.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.4.3 Merck KGaA CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.4.4 Main Business and Markets Served7.5 Mirus Bio LLC7.5.1 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.5.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.5.3 Mirus Bio LLC CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.5.4 Main Business and Markets Served7.6 Editas Medicine7.6.1 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.6.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.6.3 Editas Medicine CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.6.4 Main Business and Markets Served7.7 Takara Bio USA7.7.1 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.7.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.7.3 Takara Bio USA CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.7.4 Main Business and Markets Served7.8 Thermo Fisher Scientific7.8.1 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.8.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.8.3 Thermo Fisher Scientific CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.8.4 Main Business and Markets Served7.9 Horizon Discovery Group7.9.1 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.9.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.9.3 Horizon Discovery Group CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.9.4 Main Business and Markets Served7.10 Intellia Therapeutics7.10.1 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Production Sites and Area Served7.10.2 CRISPR And CRISPR-Associated (Cas) Genes Product Introduction, Application and Specification7.10.3 Intellia Therapeutics CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue, Price and Gross Margin (2014-2019)7.10.4 Main Business and Markets Served7.11 GE Healthcare Dharmacon 8 CRISPR And CRISPR-Associated (Cas) Genes Manufacturing Cost Analysis8.1 CRISPR And CRISPR-Associated (Cas) Genes Key Raw Materials Analysis8.1.1 Key Raw Materials8.1.2 Price Trend of Key Raw Materials8.1.3 Key Suppliers of Raw Materials8.2 Proportion of Manufacturing Cost Structure8.3 Manufacturing Process Analysis of CRISPR And CRISPR-Associated (Cas) Genes8.4 CRISPR And CRISPR-Associated (Cas) Genes Industrial Chain Analysis 9 Marketing Channel, Distributors and Customers9.1 Marketing Channel9.1.1 Direct Marketing9.1.2 Indirect Marketing9.2 CRISPR And CRISPR-Associated (Cas) Genes Distributors List9.3 CRISPR And CRISPR-Associated (Cas) Genes Customers 10 Market Dynamics10.1 Market Trends10.2 Opportunities10.3 Market Drivers10.4 Challenges10.5 Influence Factors 11 Global CRISPR And CRISPR-Associated (Cas) Genes Market Forecast11.1 Global CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue Forecast11.1.1 Global CRISPR And CRISPR-Associated (Cas) Genes Production Growth Rate Forecast (2019-2025)11.1.2 Global CRISPR And CRISPR-Associated (Cas) Genes Revenue and Growth Rate Forecast (2019-2025)11.1.3 Global CRISPR And CRISPR-Associated (Cas) Genes Price and Trend Forecast (2019-2025)11.2 Global CRISPR And CRISPR-Associated (Cas) Genes Production Forecast by Regions (2019-2025)11.2.1 North America CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue Forecast (2019-2025)11.2.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue Forecast (2019-2025)11.2.3 China CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue Forecast (2019-2025)11.2.4 Japan CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue Forecast (2019-2025)11.3 Global CRISPR And CRISPR-Associated (Cas) Genes Consumption Forecast by Regions (2019-2025)11.3.1 North America CRISPR And CRISPR-Associated (Cas) Genes Consumption Forecast (2019-2025)11.3.2 Europe CRISPR And CRISPR-Associated (Cas) Genes Consumption Forecast (2019-2025)11.3.3 China CRISPR And CRISPR-Associated (Cas) Genes Consumption Forecast (2019-2025)11.3.4 Japan CRISPR And CRISPR-Associated (Cas) Genes Consumption Forecast (2019-2025)11.4 Global CRISPR And CRISPR-Associated (Cas) Genes Production, Revenue and Price Forecast by Type (2019-2025)11.5 Global CRISPR And CRISPR-Associated (Cas) Genes Consumption Forecast by Application (2019-2025) 12 Research Findings and Conclusion 13 Methodology and Data Source13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About Us:

QY Research established in 2007, focus on custom research, management consulting, IPO consulting, industry chain research, data base and seminar services. The company owned a large basic data base (such as National Bureau of statistics database, Customs import and export database, Industry Association Database etc), experts resources (included energy automotive chemical medical ICT consumer goods etc.

Visit link:

CRISPR And CRISPR-Associated (Cas) Genes Market Size, Key Trends, Challenges and Standardization, Research, Key Players, Economic Impact and Forecast...

RIP David Perlman, the Dean of American Science Writing – Scientific American

The world will sorely miss the wit and wisdom of David Perlman, long admired as the senior statesman of American science writing, who passed away on June 19, 2020, at age 101. He was born during the 1918 flu pandemic and died in the midst of the COVID-19 pandemic. The former San Francisco Chronicle reporter andscience editor emeritus was remarkable not only for his longevityincluding more than seven decades in the news businessbut for the extraordinary breadth of his coverage, from space shots to fossil remains, womens reproductive health and nuclear disarmament.

Daves enthusiasm for each story was infectious; his curiosity about all things science was limitless. He entertained and informed generations of newspaper readers and inspired a cadre of American journalists to cover the wonders of science, as well as its influentialand sometimes controversialrole in modern society. I was one of the many kiddos fortunate enough to know Dave, first as a mentor and then as a lifelong colleague and friend.

I called him regularly, and, in recent months, he always answered with a cheerful, "I'm still alive." Wheelchair-bound in his longtime San Francisco home, Dave avidly followed newspaper and cable news coverage of the COVID-19 crisis. We reminisced about Tony Fauci, the widely admired government infectious disease guru on the White House Coronavirus Task Force who has often disagreed publicly with President Trump. We had both gotten to know Fauci while reporting on HIV/AIDS in the 1980s. "I hope he can survive under Mr. Trump. We are safer with him there," he said.

We also talked recently about one of the greatest problems facing American science: the rise of public denialism and its impact on all areas of research, from climate change to evolution. Those who distrust scientists and deny scientific findings are increasing in power, and their voices are growing louder. That worries me a lot, he said, noting the damaging effect of President Trumps anti-science stance, particularly on climate science research.

When Dave retired in August 2017, at age 98, he"was thought to be the oldest full-time reporter in the U.S.," according to the Chronicle. Known in the newsroom as "Dr. Dave,"his retirement party drew colleagues, friends, scientists, the late San Francisco mayor Ed Lee and U.S. Senator Dianne Feinstein. Dave began as a copyboy for the paper in 1940, after a starter newspaper job in Bismarck, North Dakota and also had a postwar newspaper stint in Paris before returning to the Chronicle. I still get the Chronicle every day. I wouldnt miss it. And I will continue subscribing to the Chronicle until the day I die, he said in a 100th-birthday interview on the Chronicles podcast The Big Event. With characteristic humor, he added, Maybe theres a way of sending it to the afterlife; I dont know whether there is a posthumous edition. If there is, I will be reading it.

Last November, the American Geophysical Union (AGU) announced that Dave would receive its 2019 Presidential Citation for Science and Society, in a year in which AGU and the award recipient were both 100 years old. The award celebrates Davids stellar work but also the role he has played in mentoring and inspiring generations of science journalists, said AGUs executive director Chris McEntee. AGU earlier created the David Perlman Award for Excellence in Science JournalismNewsan honor made more desirable because of its namesake.

Throughout his career, Dave earned the trust of scientists for his fair, insightful reporting. He enjoyed extraordinary firsthand access to research in the lab and the field, with globe-trotting adventures that would be envied by todays time- and money-starved science journalists. In 1964 he boarded the California Maritime Academys training ship Golden Bearwith dozens of international scientists for a two-month expedition (two months!) to study the evolution of plants and animals in the Galpagos Islands. He covered countless NASA missions, reporting from Houston on the historic moon walk by American astronauts on July 20, 1969. He spent two weeks in Antarctica with the National Science Foundation in 1972. And at age 87, he camped in Ethiopia with a University of California, Berkeley, team searching for fossils of human ancestors.

Closer to home, Dave covered the tragedy of HIV/AIDS, as the deadly epidemic unfolded in San Francisco in the 1980s and, later, as new lifesaving treatments became available to patients. He wrote about genetic engineering techniques pioneered in laboratories around the Bay Area, as well as companies that capitalized on their findings. Earthquake research was de rigueur on the California science beat.

I came to know Dave when I was a biology student at Mills College in Oakland, Calif., in the early 1970s. I concluded I didnt have the patienceor persistenceto become a scientist but loved writing for the college newspaper. I found Daves byline as the Chronicles science correspondent at the library, cold-called him and then visited him at the paper. After one conversation, I knew I wanted to be a Perlman.

Little did I know then that I had struck it richthat this smart, funny and very kind man was already a superstar among science writers. I was even more fortunate to see Dave in action when I covered the historic February 1975 Asilomar recombinant DNA conference in California for the journal BioScience. Dave and other national science reporters asked hard questions about the science, safety and ethical concerns surrounding the then new technique to cut and splice DNA into organisms.

Other Dave sightings continued after I got my first newspaper job at the Washington Star. We spent weeks at NASAs Jet Propulsion Laboratory in Pasadena, Calif., covering the first landing of a spacecraft on Mars in the July 20, 1976 Viking mission, as well as experiments looking for life on the Red Planet. I was fortunate to be part of the Perlman-led delegation of U.S. science writers that visited China in 1979, after the Mao-era Cultural Revolution ended. We started in Beijing, took an overnight train to the countryside to see a rudimentary factory and then went on to Shanghai and Guangzhou, talking with elderly Chinese scientists about everything from aquaculture to acupuncture. On a November, 2019 visit to Daves home on San Franciscos 5th Avenue, we reminisced about that trip: he recalled buying a box of Chinese birth-control devices to take back to Carl Djerassi, the late Stanford University chemist known as the father of the birth-control pill.

Dave was a New Yorker, raised on Manhattans Upper West Side, who was inspired at a young age to become a newspaper reporter after seeing the play The Front Page. He graduated from Columbia College in 1939, spending much of his time reporting and editing the student newspaper the Columbia Daily Spectator (you can read a great Perlman piece on a New York parade in the Spectators online archive) and went on to earn a graduate degree from the Columbia Journalism School in 1940. In a video interview I did with Dave in 2009, he talked about preparation for a science writing career, saying, I guess the best advice I could give is try to learn a little more science before you start than I ever had when I started. He added, As a matter of fact one of my colleagues ... was good enough to teach me and tell me what DNA stood for. And when I heard deoxyribonucleic acid, I nearly fell over cause Id never heard of the stuff. But I learned.

In another interview we did, he advised learning how to ask questions and how to make people explain the answers. Never be ashamed or afraid to pursue something that you don't understand. And then come prepared with as much background as you can possibly get. It means reading ... I dont know, Mars for Dummies or something that is highly technical, if you can. But prepare yourself. In one of his first medical stories, he heard the term bilirubin (a compound made during the break down of red blood cells) and assumed it was the name of a patient, Billy Rubin, before discovering what it actually meant.

Dave got interested in science writing in the late 1950s, after being given a book called The Nature of the Universe, by astrophysicist Fred Hoyle. He was hooked after he met a local astronomer and asked what he did for a living. He said he studied stars that are born in the Orion Nebula. I thought, My God, what an epiphany. Imagine stars being borna pregnant nebula. I wrote a whole story about that. I didnt use the word pregnancy either. But that was the start of everything, Dave recalled.

It was good timing, with the space race underway after the Soviet Union launched Sputnik 1, the first artificial Earth satellite, on October 4, 1957. He had to start science writing from scratch, with the most basic how and why reporters questions: How do you launch a small metal sphere into orbit around the Earth, and why doesnt it just fall from the sky? Basic, even humble, questions equal great science writing for the general public.

The universe is what intrigued Dave to the very end. I once asked him what he wished he could cover as a reporter in the years ahead. The quick answer was: Distant space and all that implieslooking at exoplanets and implications for the future of life itself. Closer to home, Dave said he would also want to write about the newest approaches to human disease and public health.

Dave was the ultimate mentor. Over the decades, I repeatedly saw him talking to young reporters or speaking to science journalism students. Dave spawned many science writers, as well as mentors of future science writers. Early in my career, he urged me to sponsor an American Association for the Advancement of Science mass media intern, the son of a Chronicle friend, for a summer at the Washington Star. I barely knew what I was doing, but yes, Dave prevailedthe intern was Richard Harris, who went on to a distinguished science journalism career at NPR.

Dave also did service to science writing as president of the National Association of Science Writers (19701971) and, later, of the Council for the Advancement of Science Writing, or CASW (19761980). He was always trying to improve science journalism, including making CASW-sponsored home visits to local newspapers, where he talked to reporters, editors and publishers about why covering science was important.

In 2017, U.S. science writers created the David Perlman Travel Fellowships in his honor, making more than $40,000 in personal donations to support international colleagues coming to the World Conference of Science Journalists in San Francisco.

Dave defied the odds until the end. He had a blood cancer called myelodysplastic syndrome (MDS), and went into hospice care last fall after deciding to discontinue blood transfusion treatments. His doctor expected he would die in a matter of weeks. Instead he lived for another eight months.

About now, I can hear Daves voice in my ear saying, Enough already. Despite the many accolades he received, Dave had limited tolerance for personal praise. There has never been a newspaper science reporter as in love with his craftor as good at itas Dave Perlman. Im among the many who owe him a tremendous debt of gratitude and will miss him greatly. When we last talked, he urged me to come visit on my next trip to the West Coast and ended with a cheerful "goodbye kiddo."

Goodbye to you too, kiddo. It's been swell.

Read more from the original source:

RIP David Perlman, the Dean of American Science Writing - Scientific American

Globally Leading Manufacturers of CRISPR Genome Editing product Scale up Production to Meet Sharp Spike in Demand Fueled by COVID-78 – Personal Injury…

The report on the CRISPR Genome Editing market provides a birds eye view of the current proceeding within the CRISPR Genome Editing market. Further, the report also takes into account the impact of the novel COVID-19 pandemic on the CRISPR Genome Editing market and offers a clear assessment of the projected market fluctuations during the forecast period. The different factors that are likely to impact the overall dynamics of the CRISPR Genome Editing market over the forecast period (2019-2029) including the current trends, growth opportunities, restraining factors, and more are discussed in detail in the market study.

For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2019 to 2025.

The CRISPR Genome Editing market report firstly introduced the basics: definitions, classifications, applications and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. Then it analyzed the worlds main region market conditions, including the product price, profit, capacity, production, supply, demand and market growth rate and forecast etc. In the end, the CRISPR Genome Editing market report introduced new project SWOT analysis, investment feasibility analysis, and investment return analysis.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures) of Market Report @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2602918&source=atm

The major players profiled in this CRISPR Genome Editing market report include:

The key players covered in this studyEditas MedicineCRISPR TherapeuticsHorizon DiscoverySigma-AldrichGenscriptSangamo BiosciencesLonza GroupIntegrated DNA TechnologiesNew England BiolabsOrigene TechnologiesTransposagen BiopharmaceuticalsThermo Fisher ScientificCaribou BiosciencesPrecision BiosciencesCellectisIntellia Therapeutics

Market segment by Type, the product can be split intoGenetic EngineeringGene LibraryHuman Stem CellsOthersMarket segment by Application, split intoBiotechnology CompaniesPharmaceutical CompaniesOthers

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaJapanSoutheast AsiaIndiaCentral & South America

The study objectives of this report are:To analyze global CRISPR Genome Editing status, future forecast, growth opportunity, key market and key players.To present the CRISPR Genome Editing development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.To strategically profile the key players and comprehensively analyze their development plan and strategies.To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of CRISPR Genome Editing are as follows:History Year: 2015-2019Base Year: 2019Estimated Year: 2020Forecast Year 2020 to 2026For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2602918&licType=S&source=atm

Key Market Related Questions Addressed in the Report:

Important Information that can be extracted from the Report:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2602918&source=atm

Read more:

Globally Leading Manufacturers of CRISPR Genome Editing product Scale up Production to Meet Sharp Spike in Demand Fueled by COVID-78 - Personal Injury...

Molecular Scissors Technology Market: Technological Advancement & Growth Analysis with Forecast to 2025 – Cole of Duty

The latest research report on the Molecular Scissors Technology market is an in-depth examination of this business sphere and is inclusive of information pertaining to vital parameters of the industry. The report provides details about the prevailing market trends, market share, industry size, current renumeration, periodic deliverables, and profits projections over the forecast timeframe.

Request a sample Report of Molecular Scissors Technology Market at:https://www.marketstudyreport.com/request-a-sample/2640187?utm_source=coleofduty.com&utm_medium=SP

An elaborate documentation of the Molecular Scissors Technology market performance during the analysis period is entailed in the report. Insights regarding the driving factors which will influence the market dynamics, alongside the growth pattern followed by the industry over the forecast period are presented. The report further focusses on analyzing the challenges existing in the market and growth prospects which define the business vertical over the forthcoming years.

Key highlights of the Molecular Scissors Technology market report:

Revealing the geographical landscape of the Molecular Scissors Technology market:

Summary of regional analysis presented in the Molecular Scissors Technology market report:

An exhaustive survey of Molecular Scissors Technology market with respect to product type and application scope:

Product scope:

Product types: Cas9, TALENs and MegaTALs, ZFN and Others

Major pointers mentioned in the report:

Ask for Discount on Molecular Scissors Technology Market Report at:https://www.marketstudyreport.com/check-for-discount/2640187?utm_source=coleofduty.com&utm_medium=SP

Application scope:

Application segmentation: Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering and Others

Insights entailed in the report:

Other takeaways from the Molecular Scissors Technology market report:

Elucidating details about the competitive topography of the Molecular Scissors Technology market:

Prominent players of the industry: Cibus, Cellectis, Thermo Fisher Scientific, Inc., Recombinetics, Sangamo Therapeutics, Merck, Intellia Therapeutics, Inc., Editas Medicine, Caribou Biosciences, Inc and Precision BioSciences

Key parameters included in the report which define the competitive landscape:

The Molecular Scissors Technology market report also emphasizes on major industry aspects like market concentration ratio.

For More Details On this Report:https://www.marketstudyreport.com/reports/global-molecular-scissors-technology-market-growth-status-and-outlook-2020-2025

Some of the Major Highlights of TOC covers:

Development Trend of Analysis of Molecular Scissors Technology Market

Marketing Channel

Market Dynamics

Methodology/Research Approach

Related Reports:

1. Global Leukemia Inhibitory Factor(LIF) Market Growth 2020-2025Leukemia Inhibitory Factor(LIF) market research report provides the newest industry data and industry future trends, allowing you to identify the products and end users driving Revenue growth and profitability. The industry report lists the leading competitors and provides the insights strategic industry Analysis of the key factors influencing the market.Read More: https://www.marketstudyreport.com/reports/global-leukemia-inhibitory-factor-lif-market-growth-2020-2025

2. Global Remdesivir (COVID-19) Market Growth 2020-2025Remdesivir (COVID-19) Market report characterize imperative Portion and contenders of the market regarding market estimate, volume, esteem. This report likewise covers every one of the locales and nations of the world, which demonstrates a territorial improvement status, it additionally incorporates Business Profile, Introduction, Revenue and so on.Read More: https://www.marketstudyreport.com/reports/global-remdesivir-covid-19-market-growth-2020-2025

Read More Reports On: https://www.marketwatch.com/press-release/at-47-cagr-endoscope-reprocessing-market-size-is-expected-to-exhibit-us-16856-million-by-2025-2020-06-17

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: sal[emailprotected]

Go here to read the rest:

Molecular Scissors Technology Market: Technological Advancement & Growth Analysis with Forecast to 2025 - Cole of Duty

Global Computational Breeding Market (2020-2027) With Top Growing Companies & COVID-19 Impact Analysis – Cole of Duty

With having published myriads of reports, Computational Breeding Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts delivers reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available to provide custom-made business solutions to the clients.

In this new business intelligence report, Computational Breeding Market Research serves a bunch of market forecast, structure, potential, and socioeconomic impacts associated with the global Computational Breeding market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Computational Breeding market.

Get Free sample copy of this report, @https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-computational-breeding-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146686#request_sample

The Computational Breeding market report has been fragmented into important regions that showcase worthwhile growth to the vendors. Each geographic segment has been measured based on supply-demand status, distribution, and pricing. Further, the study brings information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

The following manufacturers are covered:

NRgeneBenson HillGeneTwisterNSIPKeygeneComputomicsHi Fidelity GeneticsGeneXPro

Segment by Regions

North America

Europe

China

Japan

Southeast Asia

India

Market Segmentation based on Type:

Biotechnological MethodMolecular BreedingHybrid BreedingGenome EditingGenetic Engineering

Market Segmentation based on Application:

Oilseeds & PulsesCereals & GrainsFruits & VegetablesOther Applications

Get Your Copy at a Discounted Rate!!!

Ask For Discount https://www.globalmarketers.biz/discount_inquiry/discount/146686

Segmentation of the Computational Breeding market to target the growth outlook and trends affecting these segments.

Make An Enquiry About This Report @What does the Computational Breeding market report contain?

https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-computational-breeding-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146686#inquiry_before_buying

Readers can get the answers of the following questions while going through the Computational Breeding market report:

Browse the complete report @https://www.globalmarketers.biz/report/life-sciences/2015-2027-global-computational-breeding-industry-market-research-report,-segment-by-player,-type,-application,-marketing-channel,-and-region/146686#table_of_contents

See the original post:

Global Computational Breeding Market (2020-2027) With Top Growing Companies & COVID-19 Impact Analysis - Cole of Duty

DNA Shows Plants Are Extraordinary Chemists Making Love and War – SciTechDaily

Gardenias newly sequenced genome highlights how evolutionary tinkering transforms plants into some of natures great chemical-makers.

Plants are some of natures most extraordinary chemists. Unlike animals, they cant run from predators or pathogens. They cant uproot themselves to seek out a mate or spread their seeds.

So instead, they manufacture chemicals: toxins to kill bacteria. Bitter alkaloids to ward off herbivores. Sweet nectar and jewel-colored pigments to draw in pollinators or birds that can help disperse seeds.

Chemicals, you could say, are one of a plants ways of making love and war.

But how did trees, shrubs and flowers obtain these capabilities?

In a new study, scientists explore this question through the evolution of the gardenia, Gardenia jasminoides, an evergreen shrub with white flowers thats planted as an ornamental in the tropics.

In a new study, researchers report sequencing the species genome. Credit: YW Low

Researchers sequenced the genome of the gardenia for the first time. Then, they looked in-depth at how the plant makes a compound called crocin. This brightly colored chemical,which gives saffron its vermillion hue, is also responsible for the red-orange shade of the gardenias ripened fruits.

The study identified the genes involved in making crocin and used them to create the compound in the lab. This work which included deciphering the step-by-step process that gardenias use to synthesize crocin lays the foundation for large-scale production of the chemical, which is thought to have medicinal properties as an antioxidant.

The research also explored the origins of crocin in gardenias. The findings, which will be published on June 18 inBMC Biology,highlight the power of an evolutionary process called tandem gene duplication, in which accidental copying of DNA gives organisms flexibility to expand the arsenal of genetic tools they have at their disposal. Its just one way that plants can evolve new capabilities, but its a crucial one.

The important principle is that plants can reinvent things, says study co-author Victor Albert, PhD, a University at Buffalo biologist. They can duplicate some parts of their genetic toolkit and twiddle the functions a little. So lets say you have a screwdriver, but the head is a super-big one. Imagine you could duplicate that screwdriver, but you could grind the head to make it smaller and useful for little screws, but you also still have the original one with the big head to handle large ones. Thats what these plants are doing.

A chemical compound called crocin gives the fruits their red-orange hue. Credit: YW Low

It was exciting to uncover these molecular tricks of the trade while researching the genome of a plant so important to traditional Chinese medicine, and now to modern biomedical research as well, says the studys co-corresponding author, Jingyuan Song, PhD, from the Engineering Research Center of Chinese Medicine Resource in China, who is also affiliated with the Chinese Academy of Medical Sciences and Peking Union Medical College.

The project was led by Song and Shilin Chen, PhD, from the Engineering Research Center of Chinese Medicine Resource and China Academy of Chinese Medical Sciences, and by Giovanni Giuliano, PhD, of the Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA). The first authors were Zhichau Xu, PhD, and Xiangdong Pu, both of the Chinese Academy of Medical Sciences and Peking Union Medical College. Xu is also affiliated with the Engineering Research Center of Chinese Medicine Resource.

Albert, professor of biological sciences in the UB College of Arts and Sciences and a visiting professor at Nanyang Technological University in Singapore, and his students made important contributions, conducting bioinformatics research that helped unravel the evolutionary history of crocin and caffeine synthesis in the gardenia and coffee plants, respectively.

In a tandem duplication event, a single gene gets replicated by mistake during reproduction. Then, as a species evolves over time, the excess DNA is free to mutate and take on new functions.

In Gardenia jasminoides, tandem duplication led to the evolution of a gene that is needed for crocin synthesis, the study concludes. This form of genetic replication also enabled a close relative of the gardenia the coffee plant Coffea canephora to develop caffeine-producing genes, according to the research, which compared the gardenias DNA to that of Coffea canephora and a few other plants.

This is a case where we see the same underlying evolutionary mechanism generating these tandem duplicates to create two different biosynthetic pathways of interest in two plants, Albert says. We have coffee and gardenia, which evolved from a close common ancestor, and in one case tandem duplicates formed and went crazy in coffee to make caffeine. And in the other, they formed and went crazy in gardenia to make crocins.

Made by plants, but useful for humans, too

Crocin is found not just in gardenias, but also in the crocus plant, which produces saffron. These species didnt inherit the ability to make crocin from a common ancestor: They evolved their arsenal of genes independently. The same goes for caffeine genes in coffee, tea and chocolate plants.

Plants are playing games with multiple evolutions of interesting phytochemicals, Albert says. And, of course, all of these phytochemicals are useful to the plants, maybe in fighting against pathogens or serving as attractants to insects.

When it comes to gardenias, the fiery color of the plants fruit helps to extend the species range, helping to attract animals that eat the fruits and expel the seeds in new locations.

But while plants perform chemistry for their own good, the compounds they produce can benefit humans too. Aspirin is closely related to a compound found in willow bark. Digoxin, used sparingly to treat heart problems, comes from the foxglove plant. Crocins antioxidant properties are of interest to researchers, and now, scientists have the knowledge they need to make that chemical in the lab.

Its a known fact that the same chemical (for instance, caffeine, or crocin) can appear again and again in distant plant species, says co-corresponding author Giuliano. One outstanding question was: How do the genes involved in the biosynthesis of such chemicals appear all at once in these different species? The work we published not only describes for the first time the complete pathway to crocin biosynthesis in any plant, but also shows that the pathway evolved in gardenias through the appearance of just one gene that acts early in the pathway, while the later ones were pre-existing, and were hitchhiked for making crocin. This is an elegant demonstration, at the biochemical level, of how nature reuses and adapts pre-existing mechanisms, rather than creating completely novel ones.

Reference: Tandem gene duplications drive divergent evolution of caffeine and crocin biosynthetic pathways in plants by Zhichao Xu, Xiangdong Pu, Ranran Gao, Olivia Costantina Demurtas, Steven J. Fleck, Michaela Richter, Chunnian He, Aijia Ji, Wei Sun, Jianqiang Kong, Kaizhi Hu, Fengming Ren, Jiejie Song, Zhe Wang, Ting Gao, Chao Xiong, Haoying Yu, Tianyi Xin, Victor A. Albert, Giovanni Giuliano, Shilin Chen and Jingyuan Song, 18 June 2020, BMC Biology.DOI: 10.1186/s12915-020-00795-3

Continued here:

DNA Shows Plants Are Extraordinary Chemists Making Love and War - SciTechDaily

Church Announces Adjustments to Missionary Work, Will …

Contributed BySarah Jane Weaver, Church News editor

Sharing the gospel of Jesus Christ remains a sacred priority for The Church of Jesus Christ of Latter-day Saints, even in the current circumstances related to the COVID-19 pandemic. Church statement

In another response to the COVID-19 pandemic, temporary adjustments will be made to missionary work in The Church of Jesus Christ of Latter-day Saints, leaders announced Monday morning.

Missionaries will continue to be called to serve and assigned to labor in missions worldwide, according to a statement from Church leaders. Missionary recommendations will continue to be received, and missionary assignments for worldwide service will continue to be made.

However, in an effort to adapt to constantly changing conditions and out of an abundance of caution, Church leaders are implementing temporary adjustments to missionary service.

These changes include the following:

Young missionary elders currently serving in missions within the United States and Canada who would complete their mission on or before September 1, 2020 may be released after they have served for 21 months. The length of service for sister missionaries serving in the United States and Canada will not be impacted by the adjustments.

Young missionaries with health issues and senior missionaries may be released from service.

Some missionaries may be temporarily reassigned to another mission.

Sharing the gospel of Jesus Christ remains a sacred priority for The Church of Jesus Christ of Latter-day Saints, even in the current circumstances related to the COVID-19 pandemic, said Church leaders in a statement. We continue to monitor the spread of this condition and its impact on missionaries worldwide. We take very seriously the health and safety of our missionaries and of those they teach.

Young missionaries needing to work primarily from their apartments will continue teaching using technology, studying the scriptures, and Preach My Gospel, language learning, family history, online community service and other activities as identified by the mission president, according to the statement.

In addition, missionaries are encouraged to stay in contact with their families frequently and to take opportunities to leave their apartments for periods of exercise and fresh air, while observing wise guidelines for personal contact.

Church leaders will continue to monitor conditions and make further adjustments as needed. As a Church, we express our love and appreciation for all missionaries as they strive to teach the gospel of Jesus Christ and share His love wherever they serve, wrote leaders in the statement.

Family history missionaries work on computers and do paperwork.

Missionary work has been impacted by epidemics during other times in history.

Missionary work in Hong Kong was affected by theSARS outbreak in 2003.And following an outbreak of Ebola in Liberia, missionaries were moved out of the West African nation in August 2014; young missionaries returned in September 2015.Missionary work was also disrupted in Madagascarfollowing an outbreak of the plaguein October 2017.

In June 2009, the spread ofswine flu promptedChurch leaders to change MTC drop-off protocols. In addition, a suspectedstomach flu/norovirusimpacted 250 Latter-day Saint missionaries in the Provo Missionary Training Center in January 2013.

The Church slowed the expansion of Latter-day Saint missions during World War II. Missionary work continued, however, despite many men being drafted into military service.

Missionaries smile as they meet together outside in Mexico.

See original here:

Church Announces Adjustments to Missionary Work, Will ...

Further Adjustments to Missionary Service – The Church of …

26 March 2020 - Salt Lake City

While some missionaries will remain and complete their regular term of service, many others will be released early

The First Presidency and Quorum of the Twelve Apostles of The Church of Jesus Christ of Latter-day Saints sent the following letter March 26, 2020, to Church members around the globe. See the latest updates on how COVID-19 is impacting Saints worldwide.

Dear Brothers and Sisters,

In our letter of March 20, 2020, we indicated that the original term of service for missionaries brought back early to the United States would likely be reduced to accommodate the large number of missionaries returning from around the world.

As we evaluate changing conditions, further adjustments will be made.

To all missionaries who have served and are continuing to serve in these unique circumstances we express our deep gratitude. We love and pray for our missionaries and their families. We are grateful for the continued prayers and support of parents, loved ones, and Church members as we make every effort to help them remain safe and well in these challenging times.

Sincerely,

The First Presidency and Quorum of the Twelve Apostles

Style Guide Note:When reporting about The Church of Jesus Christ of Latter-day Saints, please use the complete name of the Church in the first reference. For more information on the use of the name of the Church, go to our online Style Guide.

See the original post here:

Further Adjustments to Missionary Service - The Church of ...

Peter Navarro: Trump call to slow Covid-19 testing was ‘tongue-in-cheek’ – The Guardian

White House adviser Peter Navarro claimed Donald Trump was being tongue-in-cheek when he claimed to have asked public health officials to slow down coronavirus testing.

Trump made the remark at a campaign rally in Tulsa, Oklahoma, on Saturday evening.

On Sunday, Navarro also told CNNs Jake Tapper he did not hear me wrong when he claimed without foundation that the virus was a product of the Chinese Communist party.

China created this pandemic, the trade adviser said. They hid the virus. They created that virus. And they sent over hundreds of thousands of Chinese citizens here to spread that around and around the world.

Whether they did that on purpose, thats an open question. But thats a fact.

Experts agree Covid-19 originated in Wuhan province, most likely in a market where live animals are sold. Trump and allies have sought to blame China for the spread of the virus, some advancing the conspiracy theory that it was created in a military lab.

Navarro told CNN: In 2006, in a book I wrote called The Coming China Wars. On page 150, I predicted that China would create a viral pandemic that could possibly kill millions.

Why did I do that at the time? Because the whole structure of that authoritarian, repressive, non-transparent society is geared towards giving us exactly what they given us, which is a pandemic.

As the Guardian reported in April, Navarro was first recruited by Trump because he wrote a string of books about the Chinese strategic threat one called Death by China despite having spent almost no time in the country and having no grasp of the language.

Five of Navarros books cited a China hand with a particularly pithy turn of phrase called Ron Vara, who turned out not to exist. The name is an anagram of Navarro and the imaginary expert operated as an alter ego, confirming the authors views.

Navarros latest comments about China were as incendiary as Trumps remarks about testing were, to many, alarming. Experts have sought to dampen fears that the US may face a second wave of infections, but only because the first isnt over.

When you have 20,000-plus infections per day, how can you talk about a second wave? Dr Anthony Fauci of the National Institutes of Health told the Associated Press. Were in the first wave. Lets get out of the first wave before you have a second wave.

According to Johns Hopkins University, the US has confirmed more than 2.2m cases and nearly 120,000 Covid-19 deaths. The real numbers are believed to be higher.

New cases have shown sudden rises in several states, but not just due to testing many states, most Republican-led are seeking to reopen from lockdown. The wearing of masks and other public health guidelines has become a political fault line, with many Americans refusing to follow such advice.

Saturdays rally in Tulsa took place amid climbing case numbers in Oklahoma and against pleas from local health officials not to stage the event at all. Six campaign staffers tested positive, but in his speech Trump said the bad part of widespread testing is that it leads to logging more cases.

The president had already used racist language aimed at China, referring to Covid-19 as kung flu. He then described testing as a double-edged sword. The US had now tested 25 million people, far more than other countries, Trump said, adding: When you do testing to that extent, youre gonna find more people, youre gonna find more cases. So I said to my people slow the testing down.

Navarro insisted Trumps comment was tongue in cheek and made in a light moment. To Tappers contention that a deadly pandemic, where almost 120,000 Americans have died might not be really a good subject for a light moment, Navarro said: He takes that absolutely seriously.

On Sunday, Oklahoma reported a record number of new cases, at 478. The states previous record of 450 new cases in a day, was set on Thursday.

Democratic presidential candidate Joe Biden criticized Trump for putting politics ahead of the safety and health of Americans. House speaker Nancy Pelosi said the president was ethically unfit and intellectually unprepared to lead.

Also on CNN, Atlanta mayor Keisha Lance Bottoms, a potential Biden running mate, said: This is no time to joke. Even if it were a joke, which it was not, it was an inappropriate joke. Do you think the people, the 120,000 families out there who are missing their loved ones thought it was funny?

Acting homeland security secretary Chad Wolf told NBCs Meet the Press the White House coronavirus taskforce is working with governors to make sure the US can open up this economy in a safe and reasonable way.

I think thats what were seeing, he said.

Wolf told CBSs Face the Nation the task force was on top of all of these outbreaks, including in Arizona, Texas, Florida and other states having hot spots. The administration, he said, had sent medical equipment, staff and personnel to assist with reopening efforts.

Bottoms also condemned Trump for staging his rally in Tulsa, the site of a historic race massacre, after a month of protests and civil unrest over racism and police brutality, subjects he skipped entirely during his speech.

That rally was an embarrassment, she said. It was absolutely what the nation does not need right now. He did not speak about healing. He did not recognize any of the racial tensions that are happening across our country.

Instead, he does what he always does. He continues to try and divide us and really inflames the worst in people. And so I just hope that this is a good sign that the country is moving on from him.

See the original post:

Peter Navarro: Trump call to slow Covid-19 testing was 'tongue-in-cheek' - The Guardian

Daughter speaks out after her father dies of Covid-19: ‘It was preventable’ – The Guardian

As her father lay dying in a hospital bed in Arizona, after testing positive for Covid-19, Lina Washington pleaded with him to keep fighting.

When they hung up, Washington scrolled through Instagram. She saw stories of friends and former classmates drinking and socializing at crowded bars and clubs, even as coronavirus infections rose exponentially across the state. Yet there they were, smiling, maskless, as if the threat had disappeared and life returned to normal.

Would they be so reckless, she wondered, if they knew that just a few miles away doctors and nurses were toiling around the clock to save her fathers life?

People dont think that it can happen to them, Washington, a high school friend and classmate, told me during a phone interview this week. And that carelessness, that hubris, that arrogance may have cost my dad his life.

Robert Edward Washington Jr died on 11 June from complications related to the virus, less than a month after returning to work as a security guard at a tribal casino in Chandler.

In the days since his death, Washington, a television sports reporter in Sacramento, California who grew up in the Phoenix area, said she has been on a warpath, demanding accountability and leadership from public officials and business leaders in the state. She has directly challenged Arizona governor Doug Ducey over his response to the pandemic, and implored him to do more to protect vulnerable residents.

His death was preventable, she said. Im speaking out to ensure nobody else has to feel this pain.

In the last few days, as new coronavirus cases in Arizona have climbed to their highest levels of the pandemic, Washington amplified her calls for stricter safety precautions. She has given interviews to every local TV news station and has spoken to the Arizona Republic. Nationally, she has been featured on ABC and MSNBC.

Some of her sharpest criticism has been expressed on Twitter.

I know my AZ friends arent taking this seriously, Washington tweeted on Thursday. I see what Old Town & Mill Ave look like every weekend on IG & its obscene. Youre putting people like my dad at risk by not wearing a mask at the very least. A Covid-19 death happened to me & could happen to you. Wake up.

On Friday, Washington filmed herself walking inside a Walmart in Tempe, after she saw multiple customers shopping without masks.

If you get sick, you get sick, she said an employee told her. She proceeded to call out Ducey in the tweet, writing: WHERE IS THE ACCOUNTABILITY?!

Two days earlier, Ducey had said he would no longer prohibit local governments from requiring face masks to slow the spread the virus, a reversal that came amid mounting pressure from mayors and public health officials. Wearing a mask for the first time at a news briefing, he conceded that coronavirus was widespread in the state and urged Arizonans to act responsibly to protect one another.

Gila River Hotels & Casinos, which operates Lone Butte, where Washingtons father worked, announced on Thursday that it would temporarily close for two weeks to protect the health and safety of our team members and guests, as the Gila River Indian Community moved to make protective face coverings mandatory on community lands.

This move comes after the death of one of your employees, my dad, who returned to work on 15 May, Washington responded.

It was the same day Arizona lifted its stay-at-home order.

Were open, Phoenix! the casino tweeted that morning, encouraging guests to come and reclaim your fun.

Washington said she begged her father to stay home. But he was stubborn, a trait she says she inherited. He told her he needed to work, to ensure he had health and life insurance.

That night, he worked at the security desk, Washington said, exposing him to nearly every customer. Employees were required to wear protective gear. Guests of the casino were encouraged to wear masks but not required to do so.

Washington said her father called her the next day and expressed his concern. He told her 80% of the people waiting to get into the casino at 4.30 in the morning werent wearing masks.

Within 10 days of him returning back to work he had tested positive for Covid and two weeks after that he was dead, she said.

I really wonder how many people were in that line that I knew, that we probably went to school with, she said, adding: I know so many people who would do that. Because its Arizona, and we dont really care about one another in ways like other communities do. Especially people who look like me and my dad.

Washingtons fathers death came amid a national reckoning over racism in America that has affected her professionally and personally. Inspired by the Black Lives Matter demonstrations, she helped start a community art project to benefit black youth organizations in Sacramento. It was just getting off the ground when she learned her father was ill.

It was a perfect storm, a black woman, in news, with a dad in the hospital with coronavirus, she said. It just all came down at once and then my worst fears were realized.

Washington said she was initially hesitant about speaking out. As a sports reporter, she would rather be talking about the Sacramento Kings NBA season than her own tragedy. But she said she felt a responsibility to use her platform to seek accountability and raise awareness.

Im just grateful that me expressing my pain is making a difference and putting a face to Covid in Arizona, she said.

Robert Washington was 68. He was a diabetic and had overcome prostate cancer. His daughter said they were acutely aware of the virus unequal toll on Black Americans, who are 2.3 times more likely to die from the disease than white Americans.

The last time Washington saw her father in person was in March. During a visit to Arizona, she asked him to sit for an interview.

Filmed in his backyard, Robert Washington recalled his adolescence in Ohio. A talented athlete, he excelled in nearly every sport he played. Football earned him a full scholarship to the University of Notre Dame in the early 1970s.

He was a devoted father who took her to dance, taught her to drive and prepared her for the challenges she would face as a black woman in an industry dominated by white men.

She also credits him with kindling her love of sports. When she was young, he who would take her to work at his shoeshine stand at what was then America West Arena, so she could watch the Phoenix Suns play.

He was my best friend, she said, her voice breaking. I wish I could call him right now.

Washington will lay her father to rest in Arizona on Sunday, Fathers Day.

Originally posted here:

Daughter speaks out after her father dies of Covid-19: 'It was preventable' - The Guardian

First Presidency Letter on Administrative Principles in …

The First Presidency of The Church of Jesus Christ of Latter-day Saints sent the following letter April 16, 2020, to Church leaders around the globe. Also see the latest updates on how COVID-19 is impacting Latter-day Saints..

We are grateful for the efforts many of you are making to follow the directions carefully from national, state, and local leaders in many countries in response to the COVID-19 pandemic. The Church of Jesus Christ of Latter-day Saints is also taking appropriate precautions and is providing assistance to those in need.

Under the present circumstances and under conditions that may exist in the future, the Church and its members will faithfully exhibit our commitment to being good citizens and good neighbors.

Attached to this letter are documents that explain administrative principles for the Church during challenging times. Directions are enclosed for essential ordinances, blessings, and other Church functions to guide leaders through the current crisis and the challenging days that are ahead.

These documents are issued in response to the disruptions in Church procedures and member activities caused by the worldwide COVID-19 pandemic. They should provide guidance as long as this pandemic exists in a particular country or region. Other directions may be issued later.

Sincerely,

The First Presidency

The rest is here:

First Presidency Letter on Administrative Principles in ...

6 Trump Staffers Test Positive For COVID-19 Ahead Of Tulsa Rally – NPR

A crowd of supporters wait for a Trump campaign rally on Saturday. This is the first political rally since the start of the coronavirus pandemic. Michael B. Thomas/Getty Images hide caption

A crowd of supporters wait for a Trump campaign rally on Saturday. This is the first political rally since the start of the coronavirus pandemic.

Six campaign staffers working on the advance team for President Trump's rally in Tulsa, Okla., have tested positive for COVID-19, the campaign said Saturday. Trump is still attending the rally.

"Per safety protocols, campaign staff are tested for COVID-19 before events. Six members of the advance team tested positive out of hundreds of tests performed, and quarantine procedures were immediately implemented," Tim Murtaugh, the campaign communications director, said in a statement. He added that none of those staffers or anyone in immediate contact with them will attend the rally. "As previously announced, all rally attendees are given temperature checks before going through security, at which point they are given wristbands, face masks and hand sanitizer."

Those face masks, however, will not be required, White House press secretary Kayleigh McEnany told reporters during a briefing Friday afternoon.

"I won't be wearing a mask," she said. "It's a personal decision. I'm tested regularly. I feel that it's safe for me to not be wearing a mask, and I'm in compliance with CDC guidelines, which are recommended but not required."

The Centers for Disease Control and Prevention recommends that everyone wear "cloth face coverings in public settings where other social distancing measures are difficult to maintain." The Trump campaign is requiring that everyone who attends the rally sign a waiver releasing the campaign and the president of any liability if guests are exposed to COVID-19.

This is the first Trump rally since the pandemic began spreading across the U.S. in February and comes amid a wide dispute over whether the rally should even take place. On Friday, the Oklahoma Supreme Court rejected an appeal in a lawsuit filed this week by a group of Tulsa residents who were fighting to have organizers enforce social distancing measures. The lawsuit said that the rally could increase the spread of COVID-19, because it is held indoors at a 19,000-seat center in Oklahoma, a state that has seen a spike in the virus. Tulsa was also supposed to be under curfew for the weekend, but it was lifted on Friday.

"Last night, I enacted a curfew at the request of Tulsa Police Chief Wendell Franklin, following consultation with the United States Secret Service based on intelligence they had received," Tulsa Mayor G.T. Bynum said in a statement. "Today, we were told the curfew is no longer necessary so I am rescinding it."

View original post here:

6 Trump Staffers Test Positive For COVID-19 Ahead Of Tulsa Rally - NPR

What a Negative COVID-19 Test Really Means – The Atlantic

Its still unclear how good COVID-19 tests are at finding these presymptomatic cases, but the timing of the test matters. As soon as the coronavirus finds its way into a new host, it hijacks cells to copy itself. The amount of virus builds over this time, peaking at or right before symptom onset, which can take two to 14 days but usually takes an average of five or six. Accordingly, public-health authorities have advised getting tested about four days after exposure.

Read: The protests will spread the coronavirus

This is a reasonable recommendation, given the knowns, but surprisingly little data exists on how early COVID-19 tests can detect infection before symptom onset. One model using COVID-19 cases from seven previously published studies suggests that the false-negative rate is 100 percent on day one of exposure, which falls to 38 percent on day five (when symptoms on average appear) and then a minimum of 20 percent on day eight. But in combing the literature, the researchers behind this model found only one case where a patient was tested before feeling sickas part of a cluster at a chalet in the French Alps. Moreover, the model doesnt address a whole other set of people who never develop symptoms at all. It gave no information about people who are permanently asymptomatic, Justin Lessler, an epidemiologist at Johns Hopkins University who co-authored that study, told me.

More data are likely to come soon. On Tuesday, the Food and Drug Administration released recommendations for labs and manufacturers that want to validate COVID-19 tests in people who dont have symptoms. (Currently, no tests are FDA-authorized for screening asymptomatic people.) Testing large numbers of asymptomatic peoplesuch as by pooling samplesto identify potential silent carriers will also be an essential part of the reopening strategy for schools and businesses.

Read: COVID-19 can last for several months

For individuals, however, the FDA cautions that negative results do not rule out infection. It asks that asymptomatic tests include this statement: Negative results must be considered in the context of an individuals recent exposures, history, presence of clinical signs and symptoms consistent with COVID-19. And this, in the face of imperfect COVID-19 tests, is key to interpreting a negative result. It depends on your probability of having COVID-19 in the first place.

Consider again the decision to visit elderly relatives after a negative test. If you have symptoms or you work in a place where youre at high risk for exposure, then even with a negative test, you might want to think really hard about it, Steven Woloshin, a co-director of the Center for Medicine and Media at the Dartmouth Institute, explained to me. If youre at low risk because you live in some remote area, youre practicing social distancing, you always wear a mask, and you feel fine, a negative test is probably a true negative. So even with widespread testing, social distancing and masks will continue to be important for controlling the spread of COVID-19.

We want to hear what you think about this article. Submit a letter to the editor or write to letters@theatlantic.com.

See the original post:

What a Negative COVID-19 Test Really Means - The Atlantic